Story perspectives

Phase 3 trial shows intismeran cuts recurrence or death 42%

By Drooid · Oct 27, 2026, 3:26 PM UTC · How we work

Summary

Story summary

Phase 3 trial shows intismeran autogene reduces recurrence or death risk by 42% versus pembrolizumab alone.
It marks first neoantigen mRNA therapy to meet a Phase 3 oncology endpoint.
U.S. National Cancer Institute and Foundation for NIH launch $200 million Therapeutic Cancer Vaccines Initiative.
Initiative will build trial networks, data standards, and infrastructure to speed personalized vaccine evidence within a decade.

1 of 1

Story summary

Phase 3 trial shows intismeran autogene reduces recurrence or death risk by 42% versus pembrolizumab alone.
It marks first neoantigen mRNA therapy to meet a Phase 3 oncology endpoint.
U.S. National Cancer Institute and Foundation for NIH launch $200 million Therapeutic Cancer Vaccines Initiative.
Initiative will build trial networks, data standards, and infrastructure to speed personalized vaccine evidence within a decade.